Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Immunovia reports positive results of the blinded clinical validation of IMMray[TM] PanCan-d blood test in USA

Stage I/II pancreatic cancers were detected with 98% specificity and 85% sensitivity in familial/hereditary risk group cohorts LUND, SWEDEN ―Immunovia today announced the successful completion of the last development milestone of IMMray™ PanCan-d blood test designed for early detection of pancreatic cancer (PDAC). The blinded validation study data demonstrated that Immunovia’s IMMray™ PanCan-d biomarker signature and CA 19-9 detects early stage I&II pancreatic cancers with a test specificity/sensitivity of 98%/85% vs familial/hereditary controls (reference PanFAM clinicaltrials.gov (

Immunovia reports improved test performance of IMMray[TM] PanCan-d in detecting early stage pancreatic cancer in high risk symptomatic patients

Stage I/II pancreatic cancer was detected with a specificity of 92% and a sensitivity of 80% in a clinical study LUND, SWEDEN ― Immunovia today announced improved performance of its blood based IMMray™ PanCan-d biomarker signature together with CA 19-9, in a clinical retrospective study. The study was designed to evaluate detection of early stage pancreatic cancer in high risk patients with non-specific but concerning symptoms. The study data demonstrate that Immunovia’s test  now detects pancreatic cancers (all stages) with 92% specificity and 81% sensitivity for this cohort, which is

Transfer of treasury shares in Ratos AB (publ)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.The board of Ratos AB (publ) ("Ratos" or the “Company”) has today resolved, pursuant to the authority granted by the annual general meeting on 10 March 2021, to transfer 4,430,762 Class B treasury shares in Ratos, representing 1.37% of the total number of shares outstanding and 0.41% of the total number of votes in the Company. The shares have been transferred to Carnegie Fonder

Genovis CFO has resigned

Genovis AB's (publ) Chief Financial Officer (CFO) Johny Humaloja has resigned from his position to take on new challenges.Johny has been employed by Genovis since 2019 and he will continue in his current role during the notice period. A process to recruit a new CFO will be initiated immediately. “During his time at Genovis, Johny has contributed to the development of the Group's financial management. I would like to thank him for his contribution to Genovis and wish him good luck in his new endeavors,” says Fredrik Olsson, CEO of Genovis

Herantis Pharma to focus on CDNF and xCDNF programs

Herantis Pharma Plc Company release, Inside Information   29 March 2021 at 9:00 PM EET Herantis Pharma Plc (“Herantis or the Company”), an innovative clinical stage biotech company pioneering new disease modifying and regenerative therapies, today announced that the Board of Directors has decided to focus all company resources on Herantis’ CDNF and xCDNF assets and to commence seeking out-licensing partners for the Lymfactin[®] program in the treatment of Breast Cancer Related Lymphedema (BCRL).  As previously announced in a press release on March 2, 2021 that while a favourable

Hansa Biopharma enters preclinical research collaboration with argenx

Collaboration to evaluate potential combination of companies’ IgG-modulating approachesLund, Sweden March 29, 2021 Hansa Biopharma AB “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that they have entered into a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies’ IgG-modulating technologies. The preclinical research collaboration is set up to explore the potential of combining imlifidase, Hansa’s IgG antibody-cleaving enzyme, and efgartigimod,

SRV Group Plc’s Board of Directors resolved share-based incentive plans for key personnel

SRV GROUP PLC     STOCK EXCHANGE RELEASE     29 MARCH 2021    20.45 EET SRV Group Plc’s Board of Directors resolved share-based incentive plans for key personnel The Board of Directors of SRV Group Plc has resolved to establish a new share-based Long-Term Incentive Plan 2021–2025 and a share-based One-off Long-Term Incentive Plan 2021–2022 directed to the Group key personnel. The Long-Term Incentive Plans aim to combine the objectives of the shareholders and the key personnel in order to increase the value of the Company in the long-term, and to strengthen the key personnel’s

SpectrumOne publishes prospectus relating to the rights issue of Units

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES, OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELASE WOULD BE ILLEGAL OR REQUIRE FURTHER REGISTRATION OR OTHER MEASURES. THIS PRESS RELASE DOES NOT CONSTITUTE AN OFFER OF ANY SECURITIES OF SPECTRUMONE AB (PUBL). PLEASE REFER TO THE SECTION “IMPORTANT INFORMATION” BELOW. SpectrumOne AB (publ) (“SpectrumOne” or the “Company)” today publishes a prospectus (the “Prospectus”) in

Organisation of SRV Group Plc’s Board of Directors and composition of Board Committees

SRV GROUP PLC     STOCK EXCHANGE RELEASE     29 MARCH 2021    20.15 EET Organisation of SRV Group Plc’s Board of Directors and composition of Board Committees SRV Group Plc’s Annual General Meeting held earlier today elected Tomi Yli-Kyyny as Chairman of the Board. In its organising meeting, SRV Group Plc’s Board of Directors has elected a Vice Chairman and the members of its Board Committees for a term ending at the closing of the Annual General Meeting in 2022. Timo Kokkila was elected as Vice Chairman of the Board of Directors. Heli Iisakka was elected as Chairman and

TR-1 - Replacement

The following announcement replaces the 'TR-1' announcement released on 29 March 2021. The indirect number of voting rights attached to shares, stated under Section 8A, has been amended to 116,036,866. All other details remain unchanged. The full amended text is shown below.   TR-1: Standard form for notification of major holdings [][][][][][][]NOTIFICATION OFMAJOR HOLDINGS(to besent to the relevantissuer and tothe FCA in MicrosoftWord format ifpossible)[i] 1a. Identity of the Independentissuer or the

Simon-Erik Ollus appointed Executive Vice President, Generation and member of Fortum Executive Management

FORTUM CORPORATION STOCK EXCHANGE RELEASE 29 MARCH 2021 AT 20:01 EEST  Simon-Erik Ollus, M.Soc.Sc. (Econ.), 42, has been appointed Executive Vice President of Fortum’s Generation division and member of Fortum’s Executive Management starting on 29 March 2021. He is succeeding Tiina Tuomela who is appointed the new CFO of Uniper and consequently has stepped down from her position at Fortum. In his new position, Mr Ollus will report to the President and CEO Markus Rauramo.  Simon-Erik Ollus has been with Fortum since 2009 and held various roles in strategy and market intelligence and has

Fortum Group to accelerate strategy execution – changes in senior management at Uniper

FORTUM CORPORATION STOCK EXCHANGE RELEASE 29 MARCH 2021 AT 20:00 EEST   · Uniper CEO Andreas Schierenbeck and Uniper CFO Sascha Bibert step down with immediate effect  · Klaus-Dieter Maubach takes over as new Uniper CEO   · Tiina Tuomela becomes new Uniper CFO  · Fortum Group CEO Markus Rauramo becomes Uniper Supervisory Board Chair  As part of the Fortum Group’s strategy update in December 2020, Fortum and its subsidiary Uniper announced they are targeting significant cooperation benefits in areas such as Nordic hydropower and physical optimisation, solar and wind

SRV commences written procedures to amend terms of its senior unsecured notes

SRV GROUP PLC    INSIDE INFORMATION    29 March 2021     20:00 EET SRV commences written procedures to amend terms of its senior unsecured notes SRV Group Plc ("SRV") announces written procedures in respect of its EUR 100,000,000 (of which EUR 62,096,000 is outstanding) senior unsecured callable fixed rate notes due 23 March 2022 (the "2022 Notes") and its EUR 75,000,000 senior unsecured callable fixed rate notes due 27 September 2023 (the "2023 Notes" and together with the 2022 Notes, the "Senior Notes") regarding potential amendments to the terms and conditions of the Senior Notes.

Stabilization notice

NOT FOR DISTRIBUTION OR PUBLICATION , DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, CANADA, NEW ZEALAND, JAPAN, SWITZERLAND OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE FURTHER REGISTRATION MEASURES. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASECarnegie Investment Bank AB (publ) (“Carnegie”), in its capacity as stabilization manager, notifies that stabilization measures have been undertaken in the RugVista Group AB (publ) (“RugVista Group” or the “Company”) share traded on

Tecnotree Corporation - Managers' transactions - Thomas

____________________________________________ Person subject to the notification requirementName: Thomas, SajanPosition: Other senior managerIssuer: Tecnotree CorporationLEI: 743700MRPVYI7ASHCX38 Notification type: INITIAL NOTIFICATIONReference number: 743700MRPVYI7ASHCX38_20210326155347_94____________________________________________ Transaction date: 2021-03-25Venue not applicableInstrument type: SHAREISIN: FI0009010227Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 118085 Unit price: 0.00 EUR Aggregated

Tecnotree Corporation - Managers' transactions - Subramanian

____________________________________________ Person subject to the notification requirementName: Subramanian, RamaseshanPosition: Other senior managerIssuer: Tecnotree CorporationLEI: 743700MRPVYI7ASHCX38 Notification type: INITIAL NOTIFICATIONReference number: 743700MRPVYI7ASHCX38_20210326155347_95____________________________________________ Transaction date: 2021-03-25Venue not applicableInstrument type: SHAREISIN: FI0009010227Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 26380 Unit price: 0.00 EUR

Tecnotree Corporation - Managers' transactions - Ravichander

____________________________________________ Person subject to the notification requirementName: Ravichander, PadmaPosition: Chief Executive OfficerIssuer: Tecnotree CorporationLEI: 743700MRPVYI7ASHCX38 Notification type: INITIAL NOTIFICATIONReference number: 743700MRPVYI7ASHCX38_20210326155347_93____________________________________________ Transaction date: 2021-03-25Venue not applicableInstrument type: SHAREISIN: FI0009010227Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 1734845 Unit price: 0.00 EUR

Tecnotree Corporation - Managers' transactions - Ranjan

____________________________________________ Person subject to the notification requirementName: Ranjan, PriyeshPosition: Chief Financial OfficerIssuer: Tecnotree CorporationLEI: 743700MRPVYI7ASHCX38 Notification type: INITIAL NOTIFICATIONReference number: 743700MRPVYI7ASHCX38_20210326155347_92____________________________________________ Transaction date: 2021-03-25Venue not applicableInstrument type: SHAREISIN: FI0009010227Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 417618 Unit price: 0.00 EUR Aggregated

Tecnotree Corporation - Managers' transactions - Monteiro

Person subject to the notification requirementName: Monteiro, AnilPosition: Other senior managerIssuer: Tecnotree CorporationLEI: 743700MRPVYI7ASHCX38 Notification type: INITIAL NOTIFICATIONReference number: 743700MRPVYI7ASHCX38_20210326155346_91____________________________________________ Transaction date: 2021-03-25Venue not applicableInstrument type: SHAREISIN: FI0009010227Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 83800 Unit price: 0.00 EUR Aggregated transactions(1): Volume: 83800 Volume weighted

Tecnotree Corporation - Managers' transactions - Martinez Navarro

____________________________________________ Person subject to the notification requirementName: Martinez Navarro, ArmandoPosition: Other senior managerIssuer: Tecnotree CorporationLEI: 743700MRPVYI7ASHCX38 Notification type: INITIAL NOTIFICATIONReference number: 743700MRPVYI7ASHCX38_20210326155346_90____________________________________________ Transaction date: 2021-03-25Venue not applicableInstrument type: SHAREISIN: FI0009010227Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 229957 Unit price: 0.00 EUR

Tecnotree Corporation - Managers' transactions - Koskelainen

____________________________________________ Person subject to the notification requirementName: Koskelainen, LeenaPosition: Other senior managerIssuer: Tecnotree CorporationLEI: 743700MRPVYI7ASHCX38 Notification type: INITIAL NOTIFICATIONReference number: 743700MRPVYI7ASHCX38_20210326155346_88____________________________________________ Transaction date: 2021-03-25Venue not applicableInstrument type: SHAREISIN: FI0009010227Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 120751 Unit price: 0.00 EUR Aggregated

Tecnotree Corporation - Managers' transactions - Ketkar

____________________________________________ Person subject to the notification requirementName: Ketkar, Sanjay RamPosition: Other senior managerIssuer: Tecnotree CorporationLEI: 743700MRPVYI7ASHCX38 Notification type: INITIAL NOTIFICATIONReference number: 743700MRPVYI7ASHCX38_20210326155346_89____________________________________________ Transaction date: 2021-03-25Venue not applicableInstrument type: SHAREISIN: FI0009010227Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 89880 Unit price: 0.00 EUR Aggregated

UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 29.03.2021

United Bankers Corporation NOTIFICATION 29.03.2021 at 18:30 UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 29.03.2021 Date 29.03.2021Exchange transaction BuyShare class UNIAVAmount 644Average price/share 12.4905 EURHighest price/share 12.5000 EURLowest price/share 12.4000 EURTotal price 9,331.88 EUR The shares held by United Bankers Corporation on 29.03.2021: UNIAV 37,749   On behalf of United Bankers Corporation  Skandinaviska Enskilda Banken AB (Publ) Antti

There are no items matching the current filter
There are no more items matching the current filter
Back to top